PE
ALLO icon

Point72 Europe’s Allogene Therapeutics ALLO Stock Holding History

Point72 Europe’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.33K Buy
+1,077
New +$1.28K ﹤0.01% 685

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Europe's ALLO Position: Q3 2025 in Review

Point72 Europe opened a new position in Allogene Therapeutics (ALLO) in Q3 2025: 1,077 shares worth $1.33K. The stake represents ﹤0.01% of the portfolio and ranks #685 among its holdings.

170 funds tracked by Wall St. Rank hold ALLO as of Q3 2025.

  • Point72 Europe held 1,077 shares of Allogene Therapeutics worth $1.33K as of Q3 2025.
  • Allogene Therapeutics was a new Point72 Europe position in Q3 2025.
  • Allogene Therapeutics made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #685 holding.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.